Quince Therapeutics sells protease inhibitor portfolio to Lighthouse Pharma for up to $150M milestones

Quince Therapeutics, Inc.

Received 7.5% of Lighthouse common stock; eligible for up to $150M in milestone payments.
Royalties: high single-digit to mid-teens on clinical-stage programs; low single-digit on preclinical.
Exclusive option to obtain rights to COR388 for animal health until June 30, 2023.
No salary increases for 2023; executives granted stock options: CEO 600k, others 110k-225k, vesting monthly over 4 years.
2022 bonus payouts: CEO $169,287, CAO $137,185, CMO $116,962, CBO $104,650.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Quince Therapeutics, Inc. entered into Asset Purchase Agreement with Lighthouse Pharmaceuticals, Inc. valued at up to $150 million (effective 2023-01-27).

Action: entry
Agreement: asset purchase
Counterparty: Lighthouse Pharmaceuticals, Inc.
Value: up to $150 million
Effective: 2023-01-27

Exact text from the filing

On January 27, 2023, Quince Therapeutics, Inc. (the “ Company ”) entered into an Asset Purchase Agreement (the “ Purchase Agreement ”) with Lighthouse Pharmaceuticals, Inc. (“ Purchaser ”) for the sale of its legacy small molecule protease inhibitor portfolio for all uses and indications throughout the world

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

Quince Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-017549

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.